The endpoints examined in this study (rate of respiratory tract infections and serum IgM level) were determined following feasibility assessment, with no long-term direct comparisons having been made between leniolisib and standard of care for these two endpoints before. The gene discussed is CD40LG; the disease is Respiratory tract infection.